Aethlon Medical (AEMD) Expected to Announce Quarterly Earnings on Wednesday

Aethlon Medical (NASDAQ:AEMD) is projected to issue its Q2 2026 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earningsummary page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings data on Wednesday, August 13th. The medical equipment provider reported ($8.50) EPS for the quarter, missing analysts’ consensus estimates of ($6.80) by ($1.70). On average, analysts expect Aethlon Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aethlon Medical Price Performance

Shares of AEMD opened at $4.52 on Wednesday. The company has a market cap of $1.18 million, a P/E ratio of -0.13 and a beta of 1.83. The stock has a fifty day moving average price of $7.98 and a 200 day moving average price of $15.97. Aethlon Medical has a 12 month low of $4.40 and a 12 month high of $84.40.

Analyst Upgrades and Downgrades

AEMD has been the subject of several analyst reports. Wall Street Zen raised shares of Aethlon Medical to a “sell” rating in a report on Saturday, August 30th. HC Wainwright reissued a “neutral” rating on shares of Aethlon Medical in a report on Thursday, August 14th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Aethlon Medical currently has an average rating of “Reduce” and an average price target of $560.00.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.